TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
View Top Employees from TG Therapeutics, Inc.Website | http://www.tgtherapeutics.com/ |
Ticker | TGTX |
Revenue | $23 million |
Employees | 344 (290 on RocketReach) |
Founded | 2011 |
Phone | (212) 554-4484 |
Fax | (212) 554-4531 |
Technologies |
JavaScript,
HTML,
PHP
+37 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Drug Manufacturing & Research, Pharmaceuticals, Science and Engineering, Hematological Malignancies, Healthcare, Health Care, TGTX-1101 (ublituximab), Medical Testing & Clinical Laboratories, Therapeutics, Non-Hodgkin'S Lymphoma |
Web Rank | 3 Million |
Keywords | Pharmaceutical Research |
Competitors | Corvus Pharmaceuticals, CymaBay Therapeutics, Kura Oncology, Inc., Otonomy, Inc, Precision Biologics |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 541714 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 3254 Companies, NAICS Code 325412 Companies, NAICS Code 32541 Companies, NAICS Code 54171 Companies |
Looking for a particular TG Therapeutics, Inc. employee's phone or email?
The TG Therapeutics, Inc. annual revenue was $23 million in 2024.
Peter Sportelli is the COO of TG Therapeutics, Inc..
290 people are employed at TG Therapeutics, Inc..
TG Therapeutics, Inc. is based in New York, New York.
The NAICS codes for TG Therapeutics, Inc. are [5417, 541714, 32, 325, 54, 541, 3254, 325412, 32541, 54171].
The SIC codes for TG Therapeutics, Inc. are [28, 283].